Long-Term Outcomes of Congenital Adrenal Hyperplasia

A plethora of negative long-term outcomes have been associated with congenital adrenal hyperplasia (CAH). The causes are multiple and involve supra-physiological gluco- and mineralocorticoid replacement, excess adrenal androgens both intrauterine and postnatal, elevated steroid precursor and adrenoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordenström, Anna, Lajic, Svetlana, Falhammar, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449109/
https://www.ncbi.nlm.nih.gov/pubmed/35799332
http://dx.doi.org/10.3803/EnM.2022.1528
_version_ 1784784219084423168
author Nordenström, Anna
Lajic, Svetlana
Falhammar, Henrik
author_facet Nordenström, Anna
Lajic, Svetlana
Falhammar, Henrik
author_sort Nordenström, Anna
collection PubMed
description A plethora of negative long-term outcomes have been associated with congenital adrenal hyperplasia (CAH). The causes are multiple and involve supra-physiological gluco- and mineralocorticoid replacement, excess adrenal androgens both intrauterine and postnatal, elevated steroid precursor and adrenocorticotropic hormone levels, living with a congenital condition as well as the proximity of the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene to other genes. This review aims to discuss the different long-term outcomes of CAH.
format Online
Article
Text
id pubmed-9449109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-94491092022-09-14 Long-Term Outcomes of Congenital Adrenal Hyperplasia Nordenström, Anna Lajic, Svetlana Falhammar, Henrik Endocrinol Metab (Seoul) Review Article A plethora of negative long-term outcomes have been associated with congenital adrenal hyperplasia (CAH). The causes are multiple and involve supra-physiological gluco- and mineralocorticoid replacement, excess adrenal androgens both intrauterine and postnatal, elevated steroid precursor and adrenocorticotropic hormone levels, living with a congenital condition as well as the proximity of the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene to other genes. This review aims to discuss the different long-term outcomes of CAH. Korean Endocrine Society 2022-08 2022-07-08 /pmc/articles/PMC9449109/ /pubmed/35799332 http://dx.doi.org/10.3803/EnM.2022.1528 Text en Copyright © 2022 Korean Endocrine Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Nordenström, Anna
Lajic, Svetlana
Falhammar, Henrik
Long-Term Outcomes of Congenital Adrenal Hyperplasia
title Long-Term Outcomes of Congenital Adrenal Hyperplasia
title_full Long-Term Outcomes of Congenital Adrenal Hyperplasia
title_fullStr Long-Term Outcomes of Congenital Adrenal Hyperplasia
title_full_unstemmed Long-Term Outcomes of Congenital Adrenal Hyperplasia
title_short Long-Term Outcomes of Congenital Adrenal Hyperplasia
title_sort long-term outcomes of congenital adrenal hyperplasia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449109/
https://www.ncbi.nlm.nih.gov/pubmed/35799332
http://dx.doi.org/10.3803/EnM.2022.1528
work_keys_str_mv AT nordenstromanna longtermoutcomesofcongenitaladrenalhyperplasia
AT lajicsvetlana longtermoutcomesofcongenitaladrenalhyperplasia
AT falhammarhenrik longtermoutcomesofcongenitaladrenalhyperplasia

Ejemplares similares